Calcium acetate, an effective phosphorus binder in patients with renal failure

Martin Mai, M. Emmett, M. S. Sheikh, C. A. Santa Ana, L. Schiller, J. S. Fordtran

Research output: Contribution to journalArticle

141 Citations (Scopus)

Abstract

Calcium salts are increasingly used as phosphorus binders in patients with chronic renal failure. Calcium carbonate is the principal salt presently utilized, however, other calcium salts may be more effective and safer phosphorus binders. Theoretical calculations, in vitro experiments, and in vivo studies in normal subjects have shown calcium acetate to be a more effective phosphorus binder than other calcium salts. This salt has not previously been studied in patients with chronic renal failure. We used a one-meal gastrointestinal balance technique to measure phosphorus absorption, calcium absorption and phosphorus binding in six patients with chronic renal failure. Calcium acetate was compared with calcium carbonate and placebo. Equivalent doses (50 mEq Ca++) of calcium acetate bound more than twice as much phosphorus (106 ± 23 mg) as calcium carbonate (43 ± 39 mg) P < 0.05. When phosphorus binding was factored for calcium absorption, calcium acetate bound 0.44 mEq HPO4(=)/mEq absorbed Ca++ compared with 0.16 mEq HPO4(=) bound/mEq Ca++ absorbed with calcium carbonate. More efficient phosphorus binding permits serum phosphorus concentration to be controlled with lower doses of calcium salts. The higher phosphorus binding/calcium absorption ratio coupled with a lower dose indicates that less calcium will be absorbed when calcium acetate is used for phosphorus control. Markedly positive calcium balance, hypercalcemia and ectopic calcification should be less likely to occur with this drug than other calcium salts.

Original languageEnglish (US)
Pages (from-to)690-695
Number of pages6
JournalKidney International
Volume36
Issue number4
StatePublished - 1989
Externally publishedYes

Fingerprint

calcium acetate
Phosphorus
Renal Insufficiency
Calcium
Salts
Calcium Carbonate
Chronic Kidney Failure

ASJC Scopus subject areas

  • Medicine(all)
  • Nephrology

Cite this

Mai, M., Emmett, M., Sheikh, M. S., Santa Ana, C. A., Schiller, L., & Fordtran, J. S. (1989). Calcium acetate, an effective phosphorus binder in patients with renal failure. Kidney International, 36(4), 690-695.

Calcium acetate, an effective phosphorus binder in patients with renal failure. / Mai, Martin; Emmett, M.; Sheikh, M. S.; Santa Ana, C. A.; Schiller, L.; Fordtran, J. S.

In: Kidney International, Vol. 36, No. 4, 1989, p. 690-695.

Research output: Contribution to journalArticle

Mai, M, Emmett, M, Sheikh, MS, Santa Ana, CA, Schiller, L & Fordtran, JS 1989, 'Calcium acetate, an effective phosphorus binder in patients with renal failure', Kidney International, vol. 36, no. 4, pp. 690-695.
Mai M, Emmett M, Sheikh MS, Santa Ana CA, Schiller L, Fordtran JS. Calcium acetate, an effective phosphorus binder in patients with renal failure. Kidney International. 1989;36(4):690-695.
Mai, Martin ; Emmett, M. ; Sheikh, M. S. ; Santa Ana, C. A. ; Schiller, L. ; Fordtran, J. S. / Calcium acetate, an effective phosphorus binder in patients with renal failure. In: Kidney International. 1989 ; Vol. 36, No. 4. pp. 690-695.
@article{1b969e3829fc43e9a1444414532bf2a4,
title = "Calcium acetate, an effective phosphorus binder in patients with renal failure",
abstract = "Calcium salts are increasingly used as phosphorus binders in patients with chronic renal failure. Calcium carbonate is the principal salt presently utilized, however, other calcium salts may be more effective and safer phosphorus binders. Theoretical calculations, in vitro experiments, and in vivo studies in normal subjects have shown calcium acetate to be a more effective phosphorus binder than other calcium salts. This salt has not previously been studied in patients with chronic renal failure. We used a one-meal gastrointestinal balance technique to measure phosphorus absorption, calcium absorption and phosphorus binding in six patients with chronic renal failure. Calcium acetate was compared with calcium carbonate and placebo. Equivalent doses (50 mEq Ca++) of calcium acetate bound more than twice as much phosphorus (106 ± 23 mg) as calcium carbonate (43 ± 39 mg) P < 0.05. When phosphorus binding was factored for calcium absorption, calcium acetate bound 0.44 mEq HPO4(=)/mEq absorbed Ca++ compared with 0.16 mEq HPO4(=) bound/mEq Ca++ absorbed with calcium carbonate. More efficient phosphorus binding permits serum phosphorus concentration to be controlled with lower doses of calcium salts. The higher phosphorus binding/calcium absorption ratio coupled with a lower dose indicates that less calcium will be absorbed when calcium acetate is used for phosphorus control. Markedly positive calcium balance, hypercalcemia and ectopic calcification should be less likely to occur with this drug than other calcium salts.",
author = "Martin Mai and M. Emmett and Sheikh, {M. S.} and {Santa Ana}, {C. A.} and L. Schiller and Fordtran, {J. S.}",
year = "1989",
language = "English (US)",
volume = "36",
pages = "690--695",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Calcium acetate, an effective phosphorus binder in patients with renal failure

AU - Mai, Martin

AU - Emmett, M.

AU - Sheikh, M. S.

AU - Santa Ana, C. A.

AU - Schiller, L.

AU - Fordtran, J. S.

PY - 1989

Y1 - 1989

N2 - Calcium salts are increasingly used as phosphorus binders in patients with chronic renal failure. Calcium carbonate is the principal salt presently utilized, however, other calcium salts may be more effective and safer phosphorus binders. Theoretical calculations, in vitro experiments, and in vivo studies in normal subjects have shown calcium acetate to be a more effective phosphorus binder than other calcium salts. This salt has not previously been studied in patients with chronic renal failure. We used a one-meal gastrointestinal balance technique to measure phosphorus absorption, calcium absorption and phosphorus binding in six patients with chronic renal failure. Calcium acetate was compared with calcium carbonate and placebo. Equivalent doses (50 mEq Ca++) of calcium acetate bound more than twice as much phosphorus (106 ± 23 mg) as calcium carbonate (43 ± 39 mg) P < 0.05. When phosphorus binding was factored for calcium absorption, calcium acetate bound 0.44 mEq HPO4(=)/mEq absorbed Ca++ compared with 0.16 mEq HPO4(=) bound/mEq Ca++ absorbed with calcium carbonate. More efficient phosphorus binding permits serum phosphorus concentration to be controlled with lower doses of calcium salts. The higher phosphorus binding/calcium absorption ratio coupled with a lower dose indicates that less calcium will be absorbed when calcium acetate is used for phosphorus control. Markedly positive calcium balance, hypercalcemia and ectopic calcification should be less likely to occur with this drug than other calcium salts.

AB - Calcium salts are increasingly used as phosphorus binders in patients with chronic renal failure. Calcium carbonate is the principal salt presently utilized, however, other calcium salts may be more effective and safer phosphorus binders. Theoretical calculations, in vitro experiments, and in vivo studies in normal subjects have shown calcium acetate to be a more effective phosphorus binder than other calcium salts. This salt has not previously been studied in patients with chronic renal failure. We used a one-meal gastrointestinal balance technique to measure phosphorus absorption, calcium absorption and phosphorus binding in six patients with chronic renal failure. Calcium acetate was compared with calcium carbonate and placebo. Equivalent doses (50 mEq Ca++) of calcium acetate bound more than twice as much phosphorus (106 ± 23 mg) as calcium carbonate (43 ± 39 mg) P < 0.05. When phosphorus binding was factored for calcium absorption, calcium acetate bound 0.44 mEq HPO4(=)/mEq absorbed Ca++ compared with 0.16 mEq HPO4(=) bound/mEq Ca++ absorbed with calcium carbonate. More efficient phosphorus binding permits serum phosphorus concentration to be controlled with lower doses of calcium salts. The higher phosphorus binding/calcium absorption ratio coupled with a lower dose indicates that less calcium will be absorbed when calcium acetate is used for phosphorus control. Markedly positive calcium balance, hypercalcemia and ectopic calcification should be less likely to occur with this drug than other calcium salts.

UR - http://www.scopus.com/inward/record.url?scp=0024453822&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024453822&partnerID=8YFLogxK

M3 - Article

VL - 36

SP - 690

EP - 695

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 4

ER -